US › Healthcare

Q32 Bio Inc (QTTB)

US · Healthcare · Biotechnology

$7.52-3.22%

Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue

Net profit

$-8.9M

EPS

$-0.44

EPS estimate

$-0.53

EPS came in at -0.44 against a street estimate of -0.53 — a beat of 17.0%.

Key statistics

Market cap

$238.5M

P/E

2.6

Forward P/E

0.0

P/B

2.68

Book value

$4.46

EPS (TTM)

$3.12

52-week high

$23.57

52-week low

$1.91

50-day MA

$12.17

200-day MA

$8.93

Beta

-0.11

Analyst view

Analysts rate Q32 Bio Inc a strong buy (6 buy, 0 hold, 0 sell out of 6) with an average price target of $39.67.

Shareholding

Insiders

2.10%

Institutions

87.73%

Largest institutional holders

Fund	Stake
Orbimed Advisors LLC	17.43%
Boxer Capital Management, LLC	13.30%
Atlas Venture Life Science Advisors, LLC	11.47%
Bvf Inc	9.92%
RA Capital Management, LLC	9.85%
Point72 Asset Management, L.P.	4.95%
Opaleye Management Inc	3.93%
Logos Global Management LP	3.38%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Q32 Bio Inc — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-10-19.